Welcome to our dedicated page for Mimedx Group news (Ticker: MDXG), a resource for investors and traders seeking the latest updates and insights on Mimedx Group stock.
MiMedx Group, Inc. (NASDAQ: MDXG) is a regenerative medicine and advanced wound care company whose activities generate frequent news across clinical, regulatory, financial, and legal fronts. The company develops and markets placental tissue–based allografts and other biomaterial products used in chronic and hard-to-heal wounds, burn care, and selected surgical applications, and it regularly updates investors and clinicians on developments affecting these businesses.
News about MiMedx often includes announcements of new product launches and portfolio expansions, such as the introduction of EPIXPRESS, a lyophilized human placental-based allograft, and the exclusive U.S. distribution agreement for RegenKit Wound Gel. The company also highlights clinical and scientific milestones, including peer-reviewed publications on Purion processed human amniotic membrane allografts and interim results from randomized controlled trials like the CAMPAIGN study evaluating EPIEFFECT in nonhealing diabetic foot ulcers.
Investors following MDXG can expect regular earnings releases, conference call details, and commentary on reimbursement policy changes, particularly regarding Medicare rules for skin substitutes and advanced wound care products. MiMedx uses press releases to discuss how reimbursement reforms may affect its market and to describe its operational and commercial positioning.
In addition, MiMedx appears in news related to legal and regulatory matters, including litigation with former employees and references to FDA communications on specific products. Coverage may also include the company’s participation in investor conferences and clinical meetings such as the Symposium on Advanced Wound Care. For those tracking MDXG, this news stream provides insight into product performance, scientific evidence, regulatory context, and corporate strategy over time.
Summary not available.
MiMedx Group (NASDAQ: MDXG) faces counterclaims from a third former employee, Jake Heikkinen, alleging the company engaged in schemes to defraud Medicare and pressure healthcare providers to use unnecessary products. Heikkinen's filing, along with two other recent complaints, accuses MiMedx of predatory sales practices and lack of transparency regarding FDA warnings about its AXIOFILL product. The counterclaims describe MiMedx's lawsuit against 10 former employees as a 'blatant intimidation tactic' and allege that the company compelled employees to sell products without proper FDA approval. These accusations follow a warning letter from the FDA to MiMedx's CEO on December 20, 2023, regarding AXIOFILL.
MIMEDX Group (Nasdaq: MDXG) has announced its participation in three upcoming investor conferences in September 2024. The company's senior management will attend the Morgan Stanley 22nd Annual Global Healthcare Conference on September 6 in New York, the Lake Street 8th Annual Big8 Best Ideas Growth Conference on September 12 in Minneapolis, and the 2024 Cantor Global Healthcare Conference on September 18 in New York.
For the Cantor conference, a webcast will be available at 8:00 AM ET. Investors interested in meeting with MIMEDX's senior management at these events are advised to contact their respective Morgan Stanley, Lake Street, or Cantor representatives.
A former MiMedx Group, Inc. (NASDAQ: MDXG) employee, Caralyn Gargan, has filed counterclaims against the company, alleging 'predatory sales practices' and 'incentivized fraud, including Medicare fraud'. This action comes in response to MiMedx's lawsuit against Gargan and nine other former employees for allegedly breaching contractual obligations. Gargan's counterclaims describe MiMedx's suit as a 'blatant intimidation tactic'.
The filing references an FDA warning letter issued to MiMedx's CEO on December 20, 2023, regarding the AXIOFILL product. Gargan claims she left MiMedx after being pressured to sell AxioFill without FDA approval. This counterclaim follows a similar action by another former employee, Lora Whooley, filed earlier this month.
MIMEDX Group, Inc. (Nasdaq: MDXG) has announced the commercial launch of HELIOGEN™ Fibrillar Collagen Matrix, a particulate xenograft product designed for complex wounds in surgical settings. This shelf-stable offering contains Type I and Type III collagen, mimicking the native composition of structural connective tissue. HELIOGEN marks MIMEDX's first xenograft option and 510(k) cleared product, complementing their existing placental-based solutions in the surgical market.
CEO Joseph H. Capper stated that this launch aligns with the company's strategic initiative to expand its surgical footprint, following the introduction of two new surgical products in late 2022. Eric Smith, SVP of Marketing & International, highlighted HELIOGEN's potential to improve patient outcomes in various surgical settings, backed by initial case studies and real-world evidence.
MIMEDX Group (NASDAQ: MDXG) reported Q2 2024 financial results with net sales of $87 million, up 7% year-over-year. The company achieved GAAP net income of $18 million and Adjusted EBITDA of $20 million (23% of net sales). Key highlights include:
- Launch of HELIOGEN™, a Fibrillar Collagen Matrix and first xenograft product
- Commencement of Randomized Controlled Trial for EPIEFFECT®
- Publication in Nature – Scientific Reports on surgical applications of placental-based allografts
Despite strong results, MIMEDX faced commercial challenges due to competitive behavior in the skin substitute market. The company expects mid-to-high single-digit net sales growth for 2024, with long-term projections of low double-digit growth and Adjusted EBITDA margin above 20%.
MIMEDX Group, Inc. (Nasdaq: MDXG) announced the publication of a peer-reviewed study in Nature – Scientific Reports, focusing on how placental-based allografts may modulate scarring and fibrosis in surgical procedures. The study, titled "Human amniotic membrane modulates collagen production and deposition in vitro," is MIMEDX's first publication in this prestigious journal.
The research evaluated two configurations of PURION processed placental-based allografts: dehydrated human amnion chorion membrane (DHACM) and lyophilized human amnion chorion membrane (LHACM). Both demonstrated modulation of collagen production, deposition, and maturation, supporting the hypothesis that amniotic membranes may interrupt pathological fibrosis and restore tissue homeostasis.
This study adds to MIMEDX's growing body of evidence and expands the understanding of their allografts' regulatory capabilities in the fibrotic process, potentially leading to improved patient outcomes in procedures where pathological fibrosis results in detrimental scarring and dysfunctional tissue.
MIMEDX Group, Inc. (Nasdaq: MDXG) has announced that it will release its second quarter 2024 operating and financial results on Wednesday, July 31, 2024, after the market closes. The company's senior management team will host a webcast and conference call to discuss the results at 4:30 p.m. Eastern Time on the same day.
Investors can access the conference call using the following information:
- U.S. Investors: 877-407-6184
- International Investors: 201-389-0877
- Conference ID: 13747365
MIMEDX has appointed Kim Moller as Chief Commercial Officer (CCO), effective June 26, 2024. Moller, previously Senior Vice President of Sales since August 2020, will now oversee marketing and international commercial operations. CEO Joseph H. Capper praised Moller's leadership in transforming MIMEDX's commercial organization into a high-performing team. Moller brings nearly 30 years of sales leadership experience from reputable firms such as 3M, Acelity, and KCI. She holds a BSN from the University of Phoenix and an MBA from Colorado Christian University.
MiMedx Group (Nasdaq: MDXG) announced participation in two upcoming investor conferences. Senior management will attend the Craig-Hallum 21st Annual Institutional Investor Conference on May 29, 2024, at the Renaissance Minneapolis Hotel in Minneapolis, MN. They will also be present at the Northland Growth Conference 2024 on June 25, which will be held virtually. Investors can arrange meetings with senior management by contacting their respective Craig-Hallum or Northland representatives.